Given the widespread use of TOP1 and TOP2 inhibitors in cancer therapy, the data obtained in the present study raise the possibility that TDP2 is a critical etiological factor in the response of tumors to TOP1 and TOP2 inhibitors. The gene discussed is TDP2; the disease is cancer.